Home / Treatments / Intra-operative Radiation Therapy
Intra-operative Radiation Therapy denials: what the review data shows
Independent reviewers have decided 32 published cases where an insurer denied Intra-operative Radiation Therapy — and they overturned the insurer 31.3% of the time. A denial for Intra-operative Radiation Therapy is a starting position, not a final answer.
Published decisions
32
2001–2026
Overturned
31.3%
10 denials reversed
By condition
Published outcomes when Intra-operative Radiation Therapy was denied for these conditions.
| Condition | Decisions | Overturned |
|---|---|---|
| Breast Cancer | 19 | 21.1% |
What the insurer actually argued
Denials fall into different categories, and they don’t succeed equally — so the reason on your letter changes how you should answer it.
| Reason given | Decisions | Overturned |
|---|---|---|
Experimental/Investigational The plan called the treatment unproven. These turn on published evidence, so the appeal is a literature argument. | 29 | 31% |
Medical Necessity The plan said the care wasn’t medically necessary. The most common fight, and the most winnable. | 3 | 33.3% |
Typical time to a decision
7 days
Most land between 7 and 8 days
Handled as urgent
81.2%
Expedited when a delay would cause harm
Recent direction
Falling
63.6% → 7.7% overturned, last three years
What the reviewers wrote
Excerpts from the independent reviewers’ published findings — the actual reasoning, quoted, not summarised.
Where the denial was overturned
Nature of Statutory Criteria/Case Summary: An enrollee has requested authorization and coverage for intraoperative radiation therapy (IORT) (CPT 77469 and 77424). Accelerated partial breast irradiation (APBI) is considered an acceptable standard treatment for patients with early stage breast cancer meeting stringent criteria. The National Comprehensive Cancer Network (NCCN) supports the use of APBI use in well selected patients with breast cancer. Based on the records provided for review, this patient meets the criteria for APBI set forth by the NCCN given her age over 50 years, tumor less than 2 cm, no lymphovascular involvement, and estrogen receptor (ER) positive tumor. Surgical margins of at least 2 mm and negative lymph nodes are also criteria and are confirmed at the time of surgery.
Nature of Statutory Criteria/Case Summary: An enrollee has requested authorization and coverage for right breast lumpectomy intraoperative radiation therapy (IORT) (CPT 77424 and 77469). Findings: The physician reviewer found that recent National Comprehensive Cancer Network (NCCN) guidelines endorse the use of IORT in the treatment of well-selected patients with breast cancer. Moreover, phase 3 studies have shown equivalent outcomes in patients who undergo standard radiation therapy and IORT.
Where the denial was upheld
Worth reading too — these show what an appeal has to overcome.
Nature of Statutory Criteria/Case Summary: An enrollee has requested authorization and coverage for intraoperative radiation therapy. At issue is whether intraoperative radiation therapy (IORT) is likely to be more beneficial for this patient’s therapy compared to other standard forms of adjuvant radiation therapy following lumpectomy. It is considered standard therapy for patients to undergo adjuvant radiation therapy after a lumpectomy as part of their treatment program. Most commonly, this radiation therapy is given post-surgery over the course of one to several weeks using a variety of treatment modalities such as external beam or interstitial brachytherapy. The American Brachytherapy Society notes that there are established consensus guidelines which establish suitable patients for IORT as well as established dosing regimens.
Findings: The physician reviewer found that Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for Intra-operative radiation therapy (IORT).At issue is whether IORT is likely to be more beneficial for this patient’s therapy compared to other standard forms of adjuvant radiation therapy following lumpectomy. It is considered standard therapy for patients to undergo adjuvant radiation therapy after a lumpectomy as part of their treatment program. Most commonly, this radiation therapy is given post-surgery over the course of one to several weeks using a variety of treatment modalities such as external beam or interstitial brachytherapy. Studies show that there are established consensus guidelines which establish suitable patients for IORT as well as established dosing regimens.
Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California outcomes — every state runs an equivalent external review, but the rates here are California’s. Excerpts are quoted verbatim from the public record and describe this treatment generally, not any individual case.
How to use this in your appeal
These are outcomes from California’s external review program — an independent physician panel that binds the insurer. Every state has an equivalent process, and internal appeals succeed even more often. Cite the outcome record for Intra-operative Radiation Therapywhen you appeal: reviewers routinely find that denials like yours didn’t hold up.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · DERIVED AGGREGATE STATISTICS ONLY · METHODOLOGY
Not legal or medical advice. Coverage Rights is a self-help tool that helps you prepare your own appeal. For advice about your specific situation, talk to a licensed attorney or your doctor.